Guam Regional Medical City announced the addition of Dr. Jee Ah "Christina" Rhee, a board-certified pulmonologist and ...

Eko Health developed an AI algorithm that, combined with noninvasive heart tests, may be able to accurately identify ...

Following an admission to the authors’ centre with severe anaemia, duodenal biopsy confirmed the diagnosis of Whipple’s ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Levy leads a team of about 40 physicians in the adult cardiology program at Memorial Healthcare System in southern Broward ...

TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...

An American College of Surgeons initiative reduced postoperative hospitalization among older adults with cancer, according to ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...